PDF(Pubmed)
Abstract：
BACKGROUND: Non-compliance to medications remains a challenging problem in schizophrenia. Newer strategies with high feasibility and acceptability are always being researched. This study aimed to assess the effectiveness of technology-based intervention in improving medication compliance in individuals with schizophrenia.
METHODS: This was a prospective intervention study where participants were required to use the SuperMD smartphone application (Digital-Health Technologies Pte Ltd, Kuala Lumpur, Malaysia) for a month. A change in the Medication Adherence Rating Scale-Malay Translation (MARS-M) and Malay Translation of Drug Adherence Inventory-9 (MDAI-9) scores indicated a change in compliance and attitude to medication. Positive and Negative Syndrome Scale (PANSS) was used to assess change in symptoms and insight. Medication compliance was also obtained from the SuperMD application. Paired T-test was used to evaluate the significance of changes in mean scores of research variables over the study period. Wilcoxon signed-rank test was used to analyze the subscale of MDAI-9 and the change in PANSS score. The Kruskal-Wallis test was used to determine the effect of the change of insight on the level of compliance with medication.
RESULTS: There were 36 participants in this study. The results showed statistically significant improvement in compliance (0.65, p ≤ 0.01) but not in attitude towards medication (0.78, p = 0.065). There was also an improvement in PANNS score (-2.58, P ≤ 0.01). There was no significant change in insight (χ2(2) = 3.802, p = 0.15). Conclusion:The use of technology-based strategies like SuperMD is effective in improving medication compliance for individuals with schizophrenia.
METHODS: This was a prospective intervention study where participants were required to use the SuperMD smartphone application (Digital-Health Technologies Pte Ltd, Kuala Lumpur, Malaysia) for a month. A change in the Medication Adherence Rating Scale-Malay Translation (MARS-M) and Malay Translation of Drug Adherence Inventory-9 (MDAI-9) scores indicated a change in compliance and attitude to medication. Positive and Negative Syndrome Scale (PANSS) was used to assess change in symptoms and insight. Medication compliance was also obtained from the SuperMD application. Paired T-test was used to evaluate the significance of changes in mean scores of research variables over the study period. Wilcoxon signed-rank test was used to analyze the subscale of MDAI-9 and the change in PANSS score. The Kruskal-Wallis test was used to determine the effect of the change of insight on the level of compliance with medication.
RESULTS: There were 36 participants in this study. The results showed statistically significant improvement in compliance (0.65, p ≤ 0.01) but not in attitude towards medication (0.78, p = 0.065). There was also an improvement in PANNS score (-2.58, P ≤ 0.01). There was no significant change in insight (χ2(2) = 3.802, p = 0.15). Conclusion:The use of technology-based strategies like SuperMD is effective in improving medication compliance for individuals with schizophrenia.
摘要：
背景：不遵守药物治疗仍然是精神分裂症的一个具有挑战性的问题。一直在研究具有高可行性和可接受性的较新策略。这项研究旨在评估基于技术的干预措施在改善精神分裂症患者用药依从性方面的有效性。
方法：这是一项前瞻性干预研究，要求参与者使用SuperMD智能手机应用程序（Digital-HealthTechnologiesPteLtd，吉隆坡,马来西亚）一个月。药物依从性评定量表-马来语翻译（MARS-M）和马来语药物依从性量表-9（MDAI-9）评分的变化表明依从性和对药物的态度发生了变化。使用阳性和阴性综合征量表（PANSS）评估症状和洞察力的变化。药物依从性也从SuperMD申请获得。使用配对T检验来评估研究变量的平均得分在研究期间的变化的显著性。采用Wilcoxon符号秩检验分析MDAI-9亚表和PANSS评分的变化。使用Kruskal-Wallis测试来确定洞察力变化对药物依从性水平的影响。
结果：本研究共有36名参与者。结果显示，依从性有统计学意义的改善（0.65，p≤0.01），但对药物治疗的态度无统计学意义（0.78，p=0.065）。PANNS评分也有改善（-2.58，P≤0.01）。洞察力无明显变化（χ2（2）=3.802，p=0.15）。结论：使用基于技术的策略如SuperMD可有效改善精神分裂症患者的用药依从性。
方法：这是一项前瞻性干预研究，要求参与者使用SuperMD智能手机应用程序（Digital-HealthTechnologiesPteLtd，吉隆坡,马来西亚）一个月。药物依从性评定量表-马来语翻译（MARS-M）和马来语药物依从性量表-9（MDAI-9）评分的变化表明依从性和对药物的态度发生了变化。使用阳性和阴性综合征量表（PANSS）评估症状和洞察力的变化。药物依从性也从SuperMD申请获得。使用配对T检验来评估研究变量的平均得分在研究期间的变化的显著性。采用Wilcoxon符号秩检验分析MDAI-9亚表和PANSS评分的变化。使用Kruskal-Wallis测试来确定洞察力变化对药物依从性水平的影响。
结果：本研究共有36名参与者。结果显示，依从性有统计学意义的改善（0.65，p≤0.01），但对药物治疗的态度无统计学意义（0.78，p=0.065）。PANNS评分也有改善（-2.58，P≤0.01）。洞察力无明显变化（χ2（2）=3.802，p=0.15）。结论：使用基于技术的策略如SuperMD可有效改善精神分裂症患者的用药依从性。
